Share Price and Basic Stock Data
Last Updated: January 19, 2026, 10:13 pm
| PEG Ratio | 2.06 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
TTK Healthcare Ltd, a prominent player in the pharmaceuticals industry, reported a share price of ₹988, with a market capitalization of ₹1,396 Cr. The company’s revenue from operations has demonstrated a steady upward trajectory, rising from ₹599 Cr in Mar 2022 to ₹725 Cr in Mar 2023, and projected to reach ₹801 Cr in Mar 2025, reflecting consistent growth in sales. Quarterly sales figures also indicate resilience, with the latest reported sales of ₹186 Cr in Sep 2023, following a peak of ₹202 Cr in Jun 2023. Despite a slight decline in subsequent quarters, the overall trend remains positive, supported by an increase in operational efficiency and market demand for healthcare products. The company’s operational profit margin (OPM) stood at a modest 3% for the latest fiscal year, suggesting a focus on maintaining profitability amid rising costs and competitive pressures in the pharmaceutical sector.
Profitability and Efficiency Metrics
TTK Healthcare’s profitability metrics indicate a mixed performance. The return on equity (ROE) was reported at 6.89%, while the return on capital employed (ROCE) was slightly higher at 9.26%. These figures are relatively low compared to industry standards, which typically expect higher returns. The company recorded a net profit of ₹66 Cr, with a net profit margin of 10.18% for FY 2025. Operating profit, however, has fluctuated; it reached ₹37 Cr in Mar 2024 but declined to ₹35 Cr in Mar 2025. The interest coverage ratio (ICR) stood at a robust 31.91x, indicating strong capacity to meet interest obligations. The cash conversion cycle, reported at 43 days, suggests that TTK Healthcare is managing its cash flow effectively, although its operational efficiency could be enhanced to improve profitability further.
Balance Sheet Strength and Financial Ratios
TTK Healthcare’s balance sheet reflects a strong financial position with total assets amounting to ₹1,281 Cr as of Mar 2025. The company maintains low borrowings of ₹27 Cr, resulting in a debt-to-equity ratio of just 0.02, indicating minimal reliance on debt financing and a conservative capital structure. Reserves have increased significantly, reaching ₹1,071 Cr, which bolsters the company’s net worth. The price-to-book value (P/BV) ratio of 1.59x suggests that the stock is trading at a reasonable valuation compared to its book value. Furthermore, the current ratio of 5.23 indicates excellent liquidity, allowing TTK Healthcare to meet short-term obligations comfortably. However, the operating profit margin (OPM) of just 3% highlights the need for improved cost management and operational efficiency to enhance overall financial health.
Shareholding Pattern and Investor Confidence
The shareholding structure of TTK Healthcare reveals a strong commitment from promoters, who hold 74.57% of the company. This significant stake demonstrates confidence in the business’s long-term prospects. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold minor stakes of 1.90% and 1.18%, respectively, which may indicate limited interest from larger institutional players. The public shareholding stood at 22.37%, with the total number of shareholders rising to 16,134 as of Sep 2025. This increase in the number of shareholders reflects growing interest in the company, despite the relatively low institutional participation. The stability of promoter holdings, coupled with a steady increase in public shareholders, suggests a positive sentiment among retail investors, although the low institutional investment may raise concerns about broader market confidence.
Outlook, Risks, and Final Insight
TTK Healthcare’s outlook is characterized by both strengths and risks. On the positive side, the company has shown resilience in revenue growth and maintains a strong balance sheet with low debt levels, which could facilitate future investments and expansions. However, profitability metrics are a concern, with low ROE and OPM that require attention to enhance shareholder returns. Additionally, the pharmaceutical sector is subject to regulatory changes and competitive pressures that could impact growth. Risks include potential fluctuations in raw material costs and the need for continual innovation to meet market demands. In a scenario of sustained revenue growth and improved operational efficiency, TTK Healthcare could enhance its profitability and market position, while failure to address these weaknesses may hinder future performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 205/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,920 Cr. | 360 | 479/192 | 81.2 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.6 Cr. | 45.3 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.7 Cr. | 39.4 | 41.0/17.0 | 137 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,907.60 Cr | 1,108.76 | 52.02 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 170 | 183 | 180 | 202 | 186 | 184 | 181 | 208 | 198 | 205 | 190 | 226 | 204 |
| Expenses | 166 | 174 | 165 | 192 | 176 | 179 | 169 | 201 | 190 | 197 | 178 | 224 | 198 |
| Operating Profit | 4 | 8 | 15 | 10 | 10 | 5 | 12 | 7 | 8 | 8 | 12 | 3 | 5 |
| OPM % | 2% | 5% | 8% | 5% | 5% | 3% | 7% | 3% | 4% | 4% | 6% | 1% | 3% |
| Other Income | 13 | 12 | 12 | 15 | 16 | 16 | 16 | 37 | 18 | 18 | 13 | 18 | 19 |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 13 | 16 | 23 | 21 | 22 | 18 | 24 | 41 | 23 | 23 | 22 | 18 | 21 |
| Tax % | 23% | 26% | 27% | 24% | 26% | 27% | 25% | 23% | 26% | 26% | 26% | 26% | 4% |
| Net Profit | 10 | 12 | 17 | 16 | 16 | 13 | 18 | 32 | 17 | 17 | 16 | 13 | 20 |
| EPS in Rs | 7.01 | 8.49 | 11.99 | 11.09 | 11.33 | 9.12 | 12.93 | 22.35 | 12.17 | 11.84 | 11.43 | 9.20 | 14.43 |
Last Updated: December 28, 2025, 6:04 pm
Below is a detailed analysis of the quarterly data for TTK Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 204.00 Cr.. The value appears to be declining and may need further review. It has decreased from 226.00 Cr. (Jun 2025) to 204.00 Cr., marking a decrease of 22.00 Cr..
- For Expenses, as of Sep 2025, the value is 198.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 224.00 Cr. (Jun 2025) to 198.00 Cr., marking a decrease of 26.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Jun 2025) to 5.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Sep 2025, the value is 3.00%. The value appears strong and on an upward trend. It has increased from 1.00% (Jun 2025) to 3.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Jun 2025) to 21.00 Cr., marking an increase of 3.00 Cr..
- For Tax %, as of Sep 2025, the value is 4.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 4.00%, marking a decrease of 22.00%.
- For Net Profit, as of Sep 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Jun 2025) to 20.00 Cr., marking an increase of 7.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 14.43. The value appears strong and on an upward trend. It has increased from 9.20 (Jun 2025) to 14.43, marking an increase of 5.23.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:28 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 416 | 483 | 519 | 528 | 578 | 628 | 646 | 476 | 599 | 725 | 753 | 801 | 825 |
| Expenses | 396 | 453 | 478 | 489 | 535 | 578 | 617 | 457 | 577 | 694 | 715 | 767 | 797 |
| Operating Profit | 20 | 30 | 40 | 38 | 43 | 50 | 28 | 19 | 22 | 31 | 37 | 35 | 28 |
| OPM % | 5% | 6% | 8% | 7% | 7% | 8% | 4% | 4% | 4% | 4% | 5% | 4% | 3% |
| Other Income | 6 | 7 | 6 | 6 | 8 | 8 | 9 | 28 | 42 | 643 | 63 | 85 | 68 |
| Interest | 3 | 4 | 3 | 3 | 5 | 3 | 3 | 2 | 3 | 5 | 3 | 3 | 3 |
| Depreciation | 3 | 6 | 7 | 12 | 15 | 15 | 14 | 13 | 13 | 13 | 13 | 8 | 9 |
| Profit before tax | 20 | 26 | 36 | 29 | 30 | 39 | 19 | 32 | 48 | 657 | 84 | 108 | 83 |
| Tax % | 37% | 39% | 36% | 36% | 40% | 38% | 37% | -44% | 13% | 3% | 25% | 25% | |
| Net Profit | 12 | 16 | 23 | 19 | 18 | 24 | 12 | 46 | 42 | 640 | 63 | 82 | 66 |
| EPS in Rs | 15.95 | 20.81 | 29.19 | 24.13 | 12.86 | 17.25 | 8.72 | 32.87 | 29.43 | 452.72 | 44.47 | 57.79 | 46.90 |
| Dividend Payout % | 25% | 22% | 17% | 21% | 39% | 29% | 34% | 18% | 34% | 2% | 22% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 33.33% | 43.75% | -17.39% | -5.26% | 33.33% | -50.00% | 283.33% | -8.70% | 1423.81% | -90.16% | 30.16% |
| Change in YoY Net Profit Growth (%) | 0.00% | 10.42% | -61.14% | 12.13% | 38.60% | -83.33% | 333.33% | -292.03% | 1432.51% | -1513.97% | 120.31% |
TTK Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 4% |
| 3 Years: | 10% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 42% |
| 3 Years: | 22% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 20% |
| 3 Years: | 9% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 26% |
| 3 Years: | 29% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 4, 2025, 2:08 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 99 | 110 | 128 | 150 | 219 | 237 | 235 | 281 | 316 | 939 | 987 | 1,051 | 1,071 |
| Borrowings | 32 | 42 | 38 | 23 | 47 | 29 | 30 | 19 | 22 | 27 | 23 | 24 | 27 |
| Other Liabilities | 102 | 115 | 128 | 104 | 127 | 136 | 152 | 180 | 207 | 189 | 183 | 192 | 184 |
| Total Liabilities | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,206 | 1,281 | 1,296 |
| Fixed Assets | 54 | 52 | 106 | 99 | 110 | 98 | 89 | 85 | 80 | 71 | 75 | 81 | 78 |
| CWIP | 2 | 46 | 1 | 0 | 1 | 2 | 9 | 0 | 0 | 3 | 1 | 0 | 0 |
| Investments | 0 | 0 | 10 | 9 | 9 | 13 | 9 | 13 | 15 | 13 | 13 | 11 | 12 |
| Other Assets | 184 | 177 | 185 | 177 | 288 | 304 | 325 | 395 | 463 | 1,083 | 1,118 | 1,189 | 1,205 |
| Total Assets | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,206 | 1,281 | 1,296 |
Below is a detailed analysis of the balance sheet data for TTK Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,071.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,051.00 Cr. (Mar 2025) to 1,071.00 Cr., marking an increase of 20.00 Cr..
- For Borrowings, as of Sep 2025, the value is 27.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 24.00 Cr. (Mar 2025) to 27.00 Cr., marking an increase of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 184.00 Cr.. The value appears to be improving (decreasing). It has decreased from 192.00 Cr. (Mar 2025) to 184.00 Cr., marking a decrease of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,296.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,281.00 Cr. (Mar 2025) to 1,296.00 Cr., marking an increase of 15.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 78.00 Cr.. The value appears to be declining and may need further review. It has decreased from 81.00 Cr. (Mar 2025) to 78.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,205.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,189.00 Cr. (Mar 2025) to 1,205.00 Cr., marking an increase of 16.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,296.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,281.00 Cr. (Mar 2025) to 1,296.00 Cr., marking an increase of 15.00 Cr..
Notably, the Reserves (1,071.00 Cr.) exceed the Borrowings (27.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -12.00 | -12.00 | 2.00 | 15.00 | -4.00 | 21.00 | -2.00 | 0.00 | 0.00 | 4.00 | 14.00 | 11.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 34 | 34 | 33 | 24 | 35 | 47 | 43 | 46 | 33 | 46 | 42 | 41 |
| Inventory Days | 64 | 62 | 66 | 65 | 80 | 77 | 101 | 123 | 102 | 89 | 105 | 107 |
| Days Payable | 56 | 50 | 53 | 100 | 130 | 101 | 121 | 170 | 134 | 116 | 110 | 106 |
| Cash Conversion Cycle | 41 | 46 | 46 | -11 | -16 | 22 | 23 | -2 | 1 | 19 | 36 | 43 |
| Working Capital Days | -24 | -31 | -38 | -24 | -30 | -6 | -3 | -32 | -28 | 4 | 49 | 48 |
| ROCE % | 17% | 20% | 23% | 18% | 15% | 15% | 8% | 6% | 8% | 10% | 9% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Axis ELSS Tax Saver Fund | 172,386 | 0.08 | 25.52 | 172,386 | 2025-04-22 15:56:52 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 57.79 | 44.47 | 452.72 | 29.43 | 32.87 |
| Diluted EPS (Rs.) | 57.79 | 44.47 | 452.72 | 29.43 | 32.87 |
| Cash EPS (Rs.) | 63.69 | 53.71 | 461.79 | 38.34 | 42.08 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 750.61 | 705.23 | 671.59 | 230.16 | 205.40 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 753.73 | 708.35 | 674.71 | 233.28 | 208.52 |
| Dividend / Share (Rs.) | 10.00 | 10.00 | 10.00 | 10.00 | 6.00 |
| Revenue From Operations / Share (Rs.) | 567.22 | 532.75 | 513.16 | 424.08 | 336.91 |
| PBDIT / Share (Rs.) | 75.07 | 70.72 | 56.39 | 27.01 | 20.70 |
| PBIT / Share (Rs.) | 69.18 | 61.48 | 47.33 | 18.11 | 11.49 |
| PBT / Share (Rs.) | 76.67 | 59.53 | 43.62 | 17.58 | 16.01 |
| Net Profit / Share (Rs.) | 57.79 | 44.47 | 452.72 | 29.43 | 32.87 |
| PBDIT Margin (%) | 13.23 | 13.27 | 10.98 | 6.36 | 6.14 |
| PBIT Margin (%) | 12.19 | 11.54 | 9.22 | 4.26 | 3.41 |
| PBT Margin (%) | 13.51 | 11.17 | 8.50 | 4.14 | 4.75 |
| Net Profit Margin (%) | 10.18 | 8.34 | 88.22 | 6.94 | 9.75 |
| Return on Networth / Equity (%) | 7.69 | 6.30 | 67.41 | 12.78 | 16.00 |
| Return on Capital Employeed (%) | 9.13 | 8.64 | 6.97 | 7.56 | 5.31 |
| Return On Assets (%) | 6.37 | 5.23 | 54.67 | 7.44 | 9.39 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.02 | 0.06 | 0.06 |
| Asset Turnover Ratio (%) | 0.64 | 0.63 | 0.83 | 1.14 | 1.03 |
| Current Ratio (X) | 5.23 | 5.50 | 5.06 | 2.03 | 1.99 |
| Quick Ratio (X) | 4.72 | 5.01 | 4.66 | 1.68 | 1.61 |
| Inventory Turnover Ratio (X) | 7.80 | 1.91 | 2.23 | 1.92 | 1.38 |
| Dividend Payout Ratio (NP) (%) | 17.30 | 22.48 | 2.20 | 20.38 | 9.12 |
| Dividend Payout Ratio (CP) (%) | 15.70 | 18.61 | 2.16 | 15.65 | 7.12 |
| Earning Retention Ratio (%) | 82.70 | 77.52 | 97.80 | 79.62 | 90.88 |
| Cash Earning Retention Ratio (%) | 84.30 | 81.39 | 97.84 | 84.35 | 92.88 |
| Interest Coverage Ratio (X) | 31.91 | 36.27 | 15.21 | 11.79 | 17.10 |
| Interest Coverage Ratio (Post Tax) (X) | 21.38 | 23.81 | 9.53 | 5.95 | 17.77 |
| Enterprise Value (Cr.) | 926.98 | 1342.13 | 639.44 | 918.42 | 488.79 |
| EV / Net Operating Revenue (X) | 1.16 | 1.78 | 0.88 | 1.53 | 1.03 |
| EV / EBITDA (X) | 8.74 | 13.43 | 8.03 | 24.06 | 16.71 |
| MarketCap / Net Operating Revenue (X) | 2.11 | 2.78 | 2.01 | 1.96 | 1.47 |
| Retention Ratios (%) | 82.69 | 77.51 | 97.79 | 79.61 | 90.87 |
| Price / BV (X) | 1.59 | 2.10 | 1.54 | 3.60 | 2.41 |
| Price / Net Operating Revenue (X) | 2.11 | 2.78 | 2.01 | 1.96 | 1.47 |
| EarningsYield | 0.04 | 0.02 | 0.43 | 0.03 | 0.06 |
After reviewing the key financial ratios for TTK Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 63.69. This value is within the healthy range. It has increased from 53.71 (Mar 24) to 63.69, marking an increase of 9.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 750.61. It has increased from 705.23 (Mar 24) to 750.61, marking an increase of 45.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 753.73. It has increased from 708.35 (Mar 24) to 753.73, marking an increase of 45.38.
- For Dividend / Share (Rs.), as of Mar 25, the value is 10.00. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 567.22. It has increased from 532.75 (Mar 24) to 567.22, marking an increase of 34.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 75.07. This value is within the healthy range. It has increased from 70.72 (Mar 24) to 75.07, marking an increase of 4.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is 69.18. This value is within the healthy range. It has increased from 61.48 (Mar 24) to 69.18, marking an increase of 7.70.
- For PBT / Share (Rs.), as of Mar 25, the value is 76.67. This value is within the healthy range. It has increased from 59.53 (Mar 24) to 76.67, marking an increase of 17.14.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
- For PBDIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 13.27 (Mar 24) to 13.23, marking a decrease of 0.04.
- For PBIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.54 (Mar 24) to 12.19, marking an increase of 0.65.
- For PBT Margin (%), as of Mar 25, the value is 13.51. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 13.51, marking an increase of 2.34.
- For Net Profit Margin (%), as of Mar 25, the value is 10.18. This value exceeds the healthy maximum of 10. It has increased from 8.34 (Mar 24) to 10.18, marking an increase of 1.84.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.69. This value is below the healthy minimum of 15. It has increased from 6.30 (Mar 24) to 7.69, marking an increase of 1.39.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 10. It has increased from 8.64 (Mar 24) to 9.13, marking an increase of 0.49.
- For Return On Assets (%), as of Mar 25, the value is 6.37. This value is within the healthy range. It has increased from 5.23 (Mar 24) to 6.37, marking an increase of 1.14.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.63 (Mar 24) to 0.64, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 5.23. This value exceeds the healthy maximum of 3. It has decreased from 5.50 (Mar 24) to 5.23, marking a decrease of 0.27.
- For Quick Ratio (X), as of Mar 25, the value is 4.72. This value exceeds the healthy maximum of 2. It has decreased from 5.01 (Mar 24) to 4.72, marking a decrease of 0.29.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.80. This value is within the healthy range. It has increased from 1.91 (Mar 24) to 7.80, marking an increase of 5.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 17.30. This value is below the healthy minimum of 20. It has decreased from 22.48 (Mar 24) to 17.30, marking a decrease of 5.18.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 15.70. This value is below the healthy minimum of 20. It has decreased from 18.61 (Mar 24) to 15.70, marking a decrease of 2.91.
- For Earning Retention Ratio (%), as of Mar 25, the value is 82.70. This value exceeds the healthy maximum of 70. It has increased from 77.52 (Mar 24) to 82.70, marking an increase of 5.18.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 84.30. This value exceeds the healthy maximum of 70. It has increased from 81.39 (Mar 24) to 84.30, marking an increase of 2.91.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 31.91. This value is within the healthy range. It has decreased from 36.27 (Mar 24) to 31.91, marking a decrease of 4.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 21.38. This value is within the healthy range. It has decreased from 23.81 (Mar 24) to 21.38, marking a decrease of 2.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 926.98. It has decreased from 1,342.13 (Mar 24) to 926.98, marking a decrease of 415.15.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.16. This value is within the healthy range. It has decreased from 1.78 (Mar 24) to 1.16, marking a decrease of 0.62.
- For EV / EBITDA (X), as of Mar 25, the value is 8.74. This value is within the healthy range. It has decreased from 13.43 (Mar 24) to 8.74, marking a decrease of 4.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.78 (Mar 24) to 2.11, marking a decrease of 0.67.
- For Retention Ratios (%), as of Mar 25, the value is 82.69. This value exceeds the healthy maximum of 70. It has increased from 77.51 (Mar 24) to 82.69, marking an increase of 5.18.
- For Price / BV (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has decreased from 2.10 (Mar 24) to 1.59, marking a decrease of 0.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.78 (Mar 24) to 2.11, marking a decrease of 0.67.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in TTK Healthcare Ltd:
- Net Profit Margin: 10.18%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.13% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.69% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 21.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.72
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.1 (Industry average Stock P/E: 52.02)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.18%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | No 6, Cathedral Road, Chennai (Madras) Tamil Nadu 600086 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. T T Raghunathan | Executive Chairman |
| Mr. S Kalyanaraman | Managing Director & CEO |
| Mr. K Shankaran | Director |
| Mr. R K Tulshan | Director |
| Dr. T T Mukund | Director |
| Mr. N Ramesh Rajan | Independent Director |
| Mr. V Ranganathan | Independent Director |
| Mr. Murali Neelakantan | Independent Director |
| Mrs. Subashree Anantkrishnan | Independent Director |
| Mrs. Hastha Shivaramakrishnan | Independent Director |
FAQ
What is the intrinsic value of TTK Healthcare Ltd?
TTK Healthcare Ltd's intrinsic value (as of 20 January 2026) is ₹943.34 which is 6.04% lower the current market price of ₹1,004.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,417 Cr. market cap, FY2025-2026 high/low of ₹1,402/975, reserves of ₹1,071 Cr, and liabilities of ₹1,296 Cr.
What is the Market Cap of TTK Healthcare Ltd?
The Market Cap of TTK Healthcare Ltd is 1,417 Cr..
What is the current Stock Price of TTK Healthcare Ltd as on 20 January 2026?
The current stock price of TTK Healthcare Ltd as on 20 January 2026 is ₹1,004.
What is the High / Low of TTK Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of TTK Healthcare Ltd stocks is ₹1,402/975.
What is the Stock P/E of TTK Healthcare Ltd?
The Stock P/E of TTK Healthcare Ltd is 20.1.
What is the Book Value of TTK Healthcare Ltd?
The Book Value of TTK Healthcare Ltd is 768.
What is the Dividend Yield of TTK Healthcare Ltd?
The Dividend Yield of TTK Healthcare Ltd is 1.00 %.
What is the ROCE of TTK Healthcare Ltd?
The ROCE of TTK Healthcare Ltd is 9.26 %.
What is the ROE of TTK Healthcare Ltd?
The ROE of TTK Healthcare Ltd is 6.89 %.
What is the Face Value of TTK Healthcare Ltd?
The Face Value of TTK Healthcare Ltd is 10.0.